EuroScientist publishes in exclusivity the Brussels Declaration on ethics & principles for science & society policy-making, launched on 17th February 2017 at the AAAS meeting. This document outlines a set of 20 principles related to the ethics and the mechanisms through which scientific evidence is taken into account as part of the policy making process for issues relevant to science and society. This declaration proposes a dramatic shift in the way scientific evidence informs policy. It suggests integrating the views of practitioners in relevant fields, thus instilling a bottom-up approach to the policy making process. This is in sharp contrast with the existing top down policy making principles. Find out more in this op-ed written exclusively for EuroScientist by some of the authors of the Brussels Declaration. Read more [...]This post was viewed 817 times.
Chief Scientific Advisers (CSAs) play a unique role in countries that have them, like Ireland, the UK, the Czech Republic and New Zealand. Here, EuroScientist explores the nature of the science adviser's role, in an exclusive interview with Mark Ferguson, CSA to the Irish Government. A timely read, as the European Commission just announced the name of the members of its high-level group of scientific advisers, as part of the new EU scientific advice mechanism. Read more [...]This post was viewed 108 times.
Policy decisions are too often political instead of being informed by evidence based considerations. Find out all about this issue by reading this special issue of EuroScientist and sharing it as widely as possible in your circles. Read more [...]This post was viewed 417 times.
To date, most toxicology tests have not been validated but they are still mandated by regulatory agencies. The question is to find suitable ways of modernising toxicology testing in the 21st century in a structured, consistent, transparent way. In this article, Thomas Hartung, Founder Evidence-Based Toxicology Collaboration (EBTC), at Johns Hopkins University Bloomberg School of Public Health, and colleagues, examine what remains to be done to address the mounting pressure exerted on industries and food and drug regulators worldwide to bring their decision-making process up-to-date with modern science. This calls for the use of a rigorous appraisal of the value of past studies under the umbrella of what has been dubbed evidence-based medicine (EBM), to be adapted in toxicology, to guarantee the safety of drug and consumer products. Read more [...]This post was viewed 54 times.
Drugs are a modern plague. It is difficult to develop effective policies and programmes based on objective evidence. Indeed,the evidence base for prevention programmes is rather patchy. Françoise Dubois-Arber, from the Institute of Social and Preventive Medicine (IUSMP) at Lausanne University Hospital, in Switzerland, shares her views on what works and what does not, when it comes to drug prevention programmes. Read more [...]This post was viewed 19 times.